[Articles] Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial

Journal content Created on 08 Sep 2026 The Lancet Oncology

• Details
• • All feed content
  • My feed content